#1 Clinical Trials Search in Europe

Bromhexine Hydrochloride

Bromhexine Hydrochloride, a mucolytic agent traditionally used to treat respiratory conditions, has gained attention in clinical trials for its potential role in treating COVID-19. This article examines various studies investigating the efficacy and safety of Bromhexine Hydrochloride, either alone or in combination with other drugs, in managing COVID-19 symptoms and preventing disease progression.

Table of Contents

What is Bromhexine Hydrochloride?

Bromhexine Hydrochloride is a medication that has been used for many years as a mucolytic agent, which means it helps break down mucus in the respiratory tract. It is commonly known by brand names such as Bisolvon and Evoquin[1]. Recently, this drug has gained attention for its potential use in treating COVID-19, the disease caused by the SARS-CoV-2 virus.

How Does Bromhexine Work?

Bromhexine works by blocking a specific enzyme in the body called TMPRSS2. This enzyme plays a crucial role in how the SARS-CoV-2 virus enters human cells[2]. By inhibiting TMPRSS2, bromhexine may help prevent the virus from infecting cells, potentially reducing the severity of COVID-19 or even preventing infection altogether.

Potential Uses in COVID-19 Treatment

Researchers are investigating several potential uses for bromhexine in the context of COVID-19:

  • Prevention of infection: Some studies are looking at whether bromhexine can help prevent healthcare workers from becoming infected with SARS-CoV-2[2].
  • Treatment of mild to moderate COVID-19: Other trials are investigating if bromhexine can help reduce the severity of symptoms in patients with mild to moderate COVID-19[3].
  • Combination therapy: Some researchers are studying the effects of combining bromhexine with other medications, such as hydroxychloroquine or N-acetylcysteine, to see if this approach is more effective than using these drugs alone[4].

Current Clinical Trials

Several clinical trials are currently underway to evaluate the effectiveness of bromhexine for COVID-19. These studies are looking at various aspects, including:

  • The ability of bromhexine to prevent infection in healthcare workers[2].
  • The effect of bromhexine on the duration and severity of COVID-19 symptoms[3].
  • The impact of bromhexine on the need for hospitalization and intensive care unit (ICU) admission[5].
  • The safety and effectiveness of bromhexine when combined with other treatments[4].

Dosage and Administration

The dosage of bromhexine used in COVID-19 studies varies, but some common regimens include:

  • 8 mg taken three times a day[2]
  • 16 mg taken three times a day[6]
  • 32 mg taken once daily[1]

It’s important to note that these dosages are being used in clinical trials and may differ from the typical dosage used for other conditions. Patients should never self-medicate with bromhexine for COVID-19 and should only take it under the guidance of a healthcare professional.

Possible Side Effects

While bromhexine is generally considered safe when used as directed, it can cause side effects in some people. Common side effects may include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Skin rash
  • Allergic reactions (in rare cases)

The ongoing clinical trials are also monitoring for any potential side effects specific to its use in COVID-19 treatment[5].

Conclusion

Bromhexine Hydrochloride is a promising candidate for COVID-19 treatment and prevention. However, it’s important to remember that research is still ongoing, and its effectiveness against COVID-19 has not yet been proven. Patients should not use bromhexine for COVID-19 without medical supervision. As always, the best ways to protect yourself from COVID-19 are to follow public health guidelines, including getting vaccinated, wearing masks, and practicing social distancing when recommended.

Aspect Details
Study Types Randomized controlled trials, double-blind studies, open-label studies
Patient Groups Healthy adults, COVID-19 patients (mild to moderate), healthcare workers
Dosages Varying from 8mg three times daily to 32mg daily
Combination Therapies Hydroxychloroquine, N-acetylcysteine, standard COVID-19 treatments
Primary Outcomes Time to clinical recovery, rate of disease progression, viral load reduction
Secondary Outcomes Changes in biomarkers, immune response, hospitalization duration, oxygen therapy needs
Safety Monitoring Adverse events, changes in vital signs, laboratory parameters
Study Durations Ranging from 14 days to 90 days

FAQ

  • What is Bromhexine Hydrochloride and why is it being studied for COVID-19? Bromhexine Hydrochloride is a mucolytic drug that helps break down mucus. It's being studied for COVID-19 because it may inhibit an enzyme called TMPRSS2, which the virus uses to enter cells. This could potentially prevent or reduce viral infection.
  • How is Bromhexine Hydrochloride being used in COVID-19 clinical trials? In clinical trials, Bromhexine Hydrochloride is being tested in various ways: alone, in combination with other drugs like hydroxychloroquine or N-acetylcysteine, and at different dosages. It's being studied for both treatment and prevention of COVID-19 in different patient groups.
  • What are the potential benefits of using Bromhexine Hydrochloride for COVID-19? Potential benefits being investigated include reducing the severity and duration of COVID-19 symptoms, preventing disease progression, lowering the risk of hospitalization or ICU admission, and possibly preventing infection in high-risk groups like healthcare workers.
  • Are there any side effects or risks associated with using Bromhexine Hydrochloride? While Bromhexine Hydrochloride is generally considered safe, clinical trials are monitoring for any adverse effects. Common side effects of Bromhexine can include nausea, vomiting, and diarrhea. The trials will help determine if there are any specific risks related to its use in COVID-19 patients.
  • When will we know if Bromhexine Hydrochloride is effective against COVID-19? The effectiveness of Bromhexine Hydrochloride against COVID-19 will be determined after the completion and analysis of ongoing clinical trials. These trials have various durations, ranging from a few weeks to several months. Results will be published once the studies are concluded and data is analyzed.

Ongoing Clinical Trials on Bromhexine Hydrochloride

  • Study comparing dalbavancin to standard antibiotic treatment for patients with periprosthetic joint infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Study of pivmecillinam compared to standard antibiotics for treating Escherichia coli urinary tract infection with fever

    Recruiting

    1 1 1
    Investigated drugs:
    Norway Sweden

  • Study on the Effectiveness of Autovaccines Compared to Antibiotics for Patients with Hip or Knee Prosthesis Infections

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study Comparing Dalbavancin to Standard Antibiotics for Patients with Staphylococcus aureus Bloodstream Infections

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on 7-Day vs. 14-Day Antibiotic Treatment for Kidney Infection in Transplant Patients Using Bromhexine Hydrochloride, Trimethoprim, and Fluoroquinolones

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Early Oral Antibiotic Treatment for Vertebral Osteomyelitis Using Cefuroxime, Dicloxacillin, and Ceftriaxone for Adult Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

  • Study of Debio 0123 and Temozolomide for Adults with Recurrent or Newly Diagnosed Glioblastoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of rituximab followed by cladribine for patients with relapsing-remitting multiple sclerosis with less than 10 years disease duration

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study comparing 3-week versus 6-week antibiotic treatment for patients with drained pyogenic liver abscess

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Comparing human normal immunoglobulin (iv) and a drug combination to prevent infections in adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma treated with CAR-T cells

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Bromhexine Hydrochloride: A mucolytic medication that helps break down mucus in the respiratory tract. It's being studied for its potential to inhibit TMPRSS2, an enzyme used by the SARS-CoV-2 virus to enter cells.
  • TMPRSS2: Transmembrane Serine Protease 2, an enzyme that the SARS-CoV-2 virus uses to enter human cells. Inhibiting this enzyme may prevent or reduce viral infection.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • RT-qPCR: Real-Time Quantitative Polymerase Chain Reaction, a laboratory technique used to detect and measure the amount of specific genetic material, such as the SARS-CoV-2 virus.
  • Placebo: A substance with no active therapeutic effect, used as a control in clinical trials to test the effectiveness of a drug.
  • Randomized Controlled Trial: A type of scientific experiment where participants are randomly assigned to different treatment groups, including a control group, to test the effectiveness of a new treatment.
  • Biomarkers: Measurable indicators of a biological state or condition, often used to track disease progression or treatment effectiveness.
  • Cytokines: Small proteins released by cells that have specific effects on the interactions and communications between cells, particularly in immune responses.
  • Viral Load: The amount of virus in an infected person's blood or other bodily fluids, often used to measure the severity of viral infections.
  • ACE2: Angiotensin-Converting Enzyme 2, a protein on the surface of many cell types that acts as a receptor for the SARS-CoV-2 virus to enter cells.

References

  1. https://clinicaltrials.gov/study/NCT04340349
  2. https://clinicaltrials.gov/study/NCT04405999
  3. https://clinicaltrials.gov/study/NCT04273763
  4. https://clinicaltrials.gov/study/NCT04928495
  5. https://clinicaltrials.gov/study/NCT04424134
  6. https://clinicaltrials.gov/study/NCT04355026